ClinicalTrials.gg
Active, not recruitingNCT02919644COREVAX-1Updated Oct 28, 2026

Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.

A Phase 2 interventional study of autologous dendritic cells loaded with autologous tumour homogenate and IL2 in Stage IV Colorectal Cancer and Curative Resection, sponsored by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS. Active, not recruiting at 2 sites in Italy. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Phase 2, Interventional, and Treatment

How we know

Updated Oct 28, 2026Now Active, not recruitingEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 429 studies in Colorectal Neoplasms with a site in Italy — 103 open to participants now, 143 under way, 18 of them phase 3. Colorectal Neoplasms · Italy.

Enrollment
306th of 329
19 · median 215
Started
2016
with 16 others
Phase 2
113 of 429
18 open now
Primary completion
2026-12
later than 52 of 142 live
Registered
172nd of 429
by date

Among the 429 studies in Colorectal Neoplasms with a site in Italy, this one is the 306th largest by enrollment of the 329 interventional ones that give a count, is one of 17 that started in 2016, is one of 113 in phase 2, reaches primary completion later than 52 of the 142 other live ones, and was the 172nd registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

103 of the 429 studies in Colorectal Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 429 studies in Colorectal Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

Single-arm, monocentric trial to assess safety and immunological efficacy of adjuvant vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer

Read the detailed description

Vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer: a phase II study.

Primary objectives: Safety Immunological efficacy, expressed as number of patients who show enhancement of the proportion of circulating immune effectors specific for a selected panel of Colon-Rectal Cancer (CRC)-associated antigens.

Secondary objectives: Clinical outcome of the patients (OS, RFS, TTR). To evaluate the predictive role of the development of a positive DTH test after at least three vaccine administrations.

To evaluate the persistence of an antitumor immune response after the completion of the vaccination program.

To evaluate the prognostic or predictive role of the enhancement of a specific immune response.

To evaluate a panel of inflammatory cytokines involved in antitumor immune response.

To evaluate the predictive role of immune cells in tumour microenvironment. To evaluate the predictive role of tumour antigen expression.

This is a two-stage, phase 2 clinical trial designed according to Simon minimax design. A 40% immune response rate would preclude further studies, while a 70% immune response rate would indicate that further studies would be warranted. Given α and β error of 0.1, the first stage will require enrolment of 7 patients. If at least 3 patients show an immune response and toxicity is acceptable, the study will proceed to the second stage and additional 12 patients will be enrolled.

The vaccine will be considered immunologically active if at least 11 patients are immunological responders.

03

Conditions studied

  • Stage IV Colorectal Cancer
  • Curative Resection

Keywords

  • vaccination
  • autologous dendritic cells
  • autologous tumour homogenate
  • curative resection
  • stage IV colorectal cancer
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must have confirmed stage IV colorectal cancer surgically treated with radical intent.
  2. The autologous surgical specimen must have been collected and sent to the Somatic Cell Therapy Lab of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST IRCCS) and must fulfil all the acceptance criteria prescribed by the Good Manufacturing practise (GMP) procedures.
  3. The patient must be disease-free, as assessed by CT scan or MRI of the chest, abdomen, pelvis performed within 60 days before enrolment. If the resected lesions had occurred in other sites, these must be also included in the baseline CT scan and in all the subsequent evaluations.
  4. The patient must have recovered (grade 1 or less by 4.0) from all the adverse events related to previous surgery.
  5. Age >18 years.
  6. (ECOG) performance status 0 or 1.
  7. Patient must have acceptable organ function, defined as:

    1. >10 g/dl
    2. White blood cells ≥4000/μl.
    3. >1500/μl.
    4. ≥100000/μl.
    5. (AST) and Alanine Aminotransferase (ALT) \<3 times the upper institutional reference level.
    6. Total \<1.5 times the upper institutional reference level.
    7. Serum creatinine \<1.5 times the upper institutional reference level.
  8. Patients aged 70 years or older must have not lower than 55% as assessed by echocardiography.
  9. Female patients of and all male patients must accept and be compliant with an highly effective method (i.e. with a failure rate of \<1% per year: double barrier method, one barrier method plus spermicidal, intrauterine device, or oral contraception) from signature and up to three months after end of study. For this purpose are considered of childbearing potential all female subjects after puberty unless they are for at least two years or are surgically sterile. Complete abstinence from sexual intercourses is acceptable if patients' lifestyle guarantees his/her strict compliance with this prescription in the judgement of the Investigator.
  10. The patient is willing and able to give written informed consent for the study.

Exclusion criteria

Exclusion Criteria:

  1. Patients with residual disease after surgery. Marginal resection of any lesion in the absence of clinically evident residual disease is acceptable.
  2. Patients who within 6 months since primary treatment of stage I-III colorectal cancer. If chemotherapy had been administered, the term must be computed since last chemotherapy dose.
  3. Patient who completed surgery more than 60 days before study enrolment.
  4. History of other neoplastic diseases in the previous 5 years, except basal cell carcinoma of the skin and in situ carcinoma of the cervix uteri treated with curative surgery.
  5. History of congenital or acquired immunodeficiency, including history of organ transplantation.
  6. Any positivity for the serologic markers of virus (HBV) (including at least anti-HBs antibodies and anti-hepatitis B core (HBc) antibodies), virus (HCV), or Treponema pallidum. The serologic tests must have been performed within 30 days before any GMP-regulated activity (i.e. surgical resection and leukapheresis). The sole positivity for antibodies against the HBV S antigen (i.e. with all other HBV markers negative) is indicative of previous HBV vaccination and therefore is acceptable.
  7. Female patients who are pregnant or nursing.
  8. Patients undergone surgery after preoperatory chemotherapy with a fluoropyrimidine plus oxaliplatin, unless they are not candidate for postoperatory chemotherapy with the same schedule in the opinion of the Investigator (e.g. for unacceptable toxicity) or refuse completion of the perioperatory treatment.
  9. Participation in another clinical trial with any agent within 30 days prior to study screening.
  10. Any active inflammatory or disease requiring systemic or other immunomodulatory agents as detailed in section 6.4, or potentially requiring such treatments during the study treatment in the judgement of the Investigator.
  11. Any clinical condition that, in the opinion of the Investigator or the Transfusion Medicine specialist, is a to leukapheresis. In addition, all patients aged 70 or older must be evaluated by a cardiology specialist before the procedure to exclude any cardiac condition and any grade 3-4 cardiac arrhythmia, even if asymptomatic.
  12. Any clinical condition that, in the opinion of the Investigator, contraindicates the subcutaneous administration of low-dose IL-2 as per protocol (see section 6.2 for details).
  13. Any uncontrolled serious intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations potentially impacting patient safety and compliance in the opinion of the Investigator.
  14. Refusal of giving written .
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Enrollment
19 participants (actual)

Study arms

  • Experimental
    vaccine + Interleukin -2 (IL2)

    autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1), followed by IL-2 given by subcutaneous injection daily for five days (days 3-7)

    Biological: autologous dendritic cells loaded with autologous tumour homogenate · Drug: IL2

Interventions

  • Biologicalautologous dendritic cells loaded with autologous tumour homogenate

    Each vaccine dose consists of 10\_7 autologous dendritic cells loaded with autologous tumor homogenate

  • DrugInterleukin-2Studies of Interleukin-2Interleukin-2 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Each vaccine dose is followed, after two days, by IL-2 as adjuvant, at a dose of 3 MU daily for five consecutive days

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    To characterize the safety of the study drugs all adverse events observed during the study will be collected and assessed using the CTCAE v 4.03 criteria . Type, incidence, and severity of the adverse events will be reported and analyzed using descriptive statistics. All patients who received at least one treatment cycle will be considered evaluable for this primary endpoint.

    Time frame: up to 24 months

  2. immunological efficacy

    Immunological efficacy will be assessed by quantifying circulating immune effectors specific for a selected panel of tumour antigens using interferon (IFN) - γELISPOT analysis . The assay determines the proportion of peptide-reactive T lymphocytes from peripheral blood mononuclear cells (PBMC) expressed as number of spot-forming Cells

    Time frame: up to 24 months

Secondary outcomes

  1. Relapse Free Survival (RFS)

    Relapse Free Survival (RFS) is calculated as the time from study enrolment to either disease recurrence, defined as above, or the date of death for any cause. Patients alive with no evidence of disease recurrence at the time of their last visit are censored at the time of the last examination.

    Time frame: up to 7 years

  2. Overall Survival (OS)

    Overall Survival (OS) is calculated as the time from study enrolment to the date of death for any cause. Patients still alive at the time of analysis are censored at the last time they are known to be alive.

    Time frame: up to 7 years

  3. Positive Delayed Type Hypersensitivity (DTH) skin test

    evaluation of the predictive role of a positive DTH test after at least three vaccine administrations

    Time frame: up 24 months

  4. Antitumor Immune response

    evaluation of the persistence of an antitumor immune response after the completion of the vaccination program assessed by ELISPOT assays

    Time frame: up to 7 years

  5. evaluation of the prognostic or predictive role of the enhancement of a specific immune response

    evaluation of the prognostic or predictive role of the enhancement of a specific immune response assessed by ELISPOT

    Time frame: up to 7 years

  6. evaluation of a panel of inflammatory cytokines involved in antitumor immune response

    Serum sampling will allow the evaluation of a panel of inflammatory cytokines during and after treatment and their concentration will be evaluated by SearchLight multiplex array analysis according to manufacturer's instructions (FDA-validated test)

    Time frame: up to 24 months

  7. evaluation of the predictive role of tumour antigen expression

    Immunohistochemistry on formalin-fixed, paraffin-embedded tumour samples will allow to evaluate the expression of tumour-associated antigen

    Time frame: up to 24 months

  8. evaluation of the predictive role of immune cells in tumor microenvironment

    Immunohistochemistry on formalin-fixed, paraffin-embedded tumour samples will allow to characterize the immune infiltrate

    Time frame: up to 24 months

07

Study locations

2 sites
  • UO Immunoterapia e Laboratorio TCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) S.r.l IRCCS
    Meldola, FC 47014, Italy
  • CRO-IRCCS Aviano
    Aviano, Italy
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2016 (actual). Primary completion is estimated for Dec 2026, 120 months after the start.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 120 months is above that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2016
First posted
Sep 29, 2016
StartActual
Dec 2, 2016
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2031
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Recruiting→Active, not recruiting
    + 7 other changes: identifiers, verification date, design details, arm descriptions, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02919644
Lead sponsor
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Responsible party
Sponsor
First posted
Sep 29, 2016
Start date
Dec 2, 2016
Primary completion
Dec 2026 (estimated)
Completion
Dec 2031 (estimated)
Last update
Oct 28, 2026

Study contacts

Francesco De Rosa, MD
principal investigator · UO Immunoterapia e Laboratorio TCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) S.r.l IRCCS

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interleukin-2

Start the discussion